Harnessing the Full Potential of Protein Degradation through Identification of Novel Targets
f5 Therapeutics is a privately held, pharmaceutical company that focuses on targeted protein degradation via ‘molecular glues.’ Our NExMod™ (Neosubstrate Expression Modulators) platform focuses on discovering novel targets for degradation to combat human disease across multiple therapeutic areas. Utilizing our proprietary methods, we have discovered multiple novel neosubstrates with the potential to revolutionize cancer care.
In addition to our monotherapy assets, we are committed to exploring our library conjugated with antibodies. While there is great momentum in the ADC world, there are still shortcomings in traditional ADC development. A growing interest in utilizing targeted protein degraders instead of cytotoxic agents as the ADC payload has garnered very recent headlines. These ‘Degrader Antibody Conjugates’ are growing in interest to big pharma and f5 Therapeutics wants to be at the forefront of this wave of innovation. We have discovered a number of novel 'warheads' we are looking to get into PoC testing through funding/partnering.